Ghent University

NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- LEXEO Therapeutics Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company, today announced the appointment of Tim Van Hauwermeiren, co-founder and Chief Executive Officer of argenx SE, as an independent, non-executive director to its Board of Directors. Mr. Van Hauwermeiren is a seasoned biotech executive with over two decades of experience in both general management and business development across the life sciences and consumer goods industries. “Tim is a highly accomplished life-sciences entrepreneur who has built one of Europe’s most successful biotech companies, and I am thrilled to welcome him to our Board of Directors,” said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. “Tim’s deep and relevant experience in company building from clinical to commercial stage will be an invaluable asset to Lexeo as we embark on our next phase of growth and progress our pipeline into later stages of clinical and commercial development.” Mr. Van Hauwermeiren is co-founder, CEO and a Board Member of argenx, a global immunology company valued at almost $25 billion focused on severe autoimmune diseases. During his 15-year tenure, he has overseen the development and launch of the company’s first commercial product, efgartigimod, for the treatment of multiple severe autoimmune diseases, and he has expanded the company’s footprint across Europe, the U.S. and Asia. Additionally during his time at argenx, Mr. Van Hauwermeiren has secured more than $4 billion in funding through equity raises and business development transactions with major pharmaceutical companies. Prior to argenx, Mr. Van Hauwermeiren held roles with increasing levels of responsibility at Ablynx and Procter & Gamble. “I am honored to join Lexeo’s Board at this important stage in the company’s growth,” said Mr. Van Hauwermeiren. “I am impressed by the company’s innovative science, pipeline and bold thinking, and I look forward to sharing my experiences and learnings with the management team as we work to bring life-changing therapies to patients with devastating genetic diseases.” Mr. Van Hauwermeiren also serves on the Board of Directors of iTeos Pharmaceuticals, and previously served on the Board of Directors of RayzeBio prior to the company’s acquisition by Bristol Myers Squibb. He holds a B.Sc. and M.Sc. in bioengineering from Ghent University and an Executive MBA from The Vlerick School of Management. About Lexeo Therapeutics Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease are treated. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimer’s disease programs. Media Response: Janine Bogris (201) 245-6838 janine.bogris@inizioevoke.com

Poster Presentation Details Visualization of Low-Voltage ECGs Hidden by Ablation Energy Artifact COPENHAGEN, Denmark, April 8, 2024 /PRNewswire/ -- CathVision today announced data from the PVISION trial demonstrating the ability of the ECGenius System's predictive noise filter to increase the time window before noise saturates PV potentials during PVI procedures. The data will be presented in a poster presentation at EHRA 2024.1 Continue Reading A sub-analysis of the PVISION trial, led by Prof. Dr. Jan De Pooter at the University of Ghent, included 68 veins treated from 24 patients who underwent a PVI procedure providing sufficient information about the start and end of the energy delivery cycle. Key data points include: Predictive noise filter increases the time window before noise saturates PV potentials during PVI procedures. Post this Of the 68 veins treated, 33 exhibited power line noise on one or more bipolar traces during the freeze cycle (49%). The mean amplitude of PV potentials before application of energy was 0.49 mV (SD 0.79 mV) and the mean time to artifact exceeding this level was 69+/-50 seconds, across all bipolar traces with ablation noise present. After applying the intelligent zero-delay predictive filter, the mean time to artifact exceeding the baseline PV amplitude increased to 82 seconds (SD 57 seconds; P < 0.001) across all bipolar traces with ablation noise present. In 44 veins, the noise amplitude never exceeded the PV potential amplitude on any of the bipolar traces during the freeze after applying the intelligent filter. Paired analysis of the average time of noise exceeding the PV potential amplitude was 116 seconds before application of the predictive filter and 26 seconds with the filter applied. "Viewing pulmonary vein potentials in real-time throughout an ablation procedure and assessing the time to isolation is critical to achieving acute success that is linked to long-term freedom from AF for patients," said Prof. Dr. Jan de Pooter, Ghent University (Belgium). "When we employed the predictive filter using the ECGenius System, the noise was eliminated from the electrogram data during the PVI procedure. The clarity this provides is outstanding and unprecedented." Poster Details EHRA 2024 April 7-9 "Intelligent Filter To Remove Artifact During Cryo Freezing For Pulmonary Vein Isolation Increases The Time Window For Observation Of Time Of Isolation" Authors: Prof. Dr. Jan De Pooter, Karl Firth, Rune Paamand, Dr. Martin Valvik "This study is the latest demonstration of CathVision's proven ability to develop differentiated technology that advances the data from EP recording systems to help EPs make accurate treatment decisions," said Mads Matthiesen, CEO of CathVision. "We know signal noise and artifacts can create a false reality. ECGenius System's innovative, predictive filter is designed to intelligently remove artifacts, exposing small signals hidden by significant energy delivery, creating a more accurate depiction of pulmonary vein isolation. This is another example of why the accepted standard for EP recording systems must change. Improving cardiac signal data is the foundation for improving procedural outcomes." For more information about ECGenius System and CARDIALYTICS, or to meet with CathVision at EHRA 2024, please contact us and connect on LinkedIn. About CathVision CathVision is a medical technology company that develops electrophysiology solutions centered around an innovative EP recording system and AI algorithm platform – the ECGenius System with CARDIALYTICS. Committed to empowering physicians to make more informed clinical decisions in the EP lab, CathVision is redefining the necessity of exceptional cardiac electrical signals to diagnose, characterize, and treat the most common heart rhythm disorders. CathVision was founded in 2013 and is headquartered in Denmark with a U.S. office in Minnesota. Follow CathVision: Twitter/X and LinkedIn 1 ECGenius System is cleared for sale in the US. Not approved for sale in the rest of the world. SOURCE CathVision

The development of hair was of central importance for the evolution of mammals and thus also of humans. However, the evolutionary origin of the genetic program of hair was previously unknown. Researchers have now been able to show that important hair components and their genetic control have already evolved in amphibians. Human hair therefore shows unexpected similarities to the claws of clawed frogs. The development of hair was of central importance for the evolution of mammals and thus also of humans. However, the evolutionary origin of the genetic programme of hair was previously unknown. An international research team led by Leopold Eckhart from MedUni Vienna has now been able to show that important hair components and their genetic control have already evolved in amphibians. Human hair therefore shows unexpected similarities to the claws of clawed frogs. The results were recently published in the scientific journal Nature Communications. In order to investigate the evolution of skin appendages, which include human hair and nails, the MedUni Vienna research team, in collaboration with the University of Ghent (Belgium), used the tropical clawed frog (Xenopus tropicalis) as an experimental model. The study revealed that the cornified claws of Xenopus frogs consist of special proteins (keratins) that are very similar to the main components of mammalian hair and nails. The formation of these keratins was found to be controlled by a specific gene, Hoxc13, in both humans and frogs. "It is known that patients with mutations in the Hoxc13 gene have defects in the growth of hair and nails. In our study, we were able to block the formation of claws in the clawed frog by switching off this gene," reports Leopold Eckhart from MedUni Vienna's Department of Dermatology. These results indicate that the genetic programme for the development of keratinized claws originated in a common ancestor of humans and frogs. "During the evolution of mammals, the programme of claw formation was modified for the development of hair," says Eckhart. Important research question clarified The evolution of terrestrial vertebrates is characterized by the appearance of an effective skin barrier against water loss in a dry environment and by the development of hard, keratinized skin appendages such as claws, scales, feathers and hair, which are crucial for catching prey, protection, supporting special types of locomotion and thermal insulation. The evolution of skin appendages is therefore an important research question. The findings from the project, which is funded by the Austrian Science Fund (FWF), contribute to clarifying the evolutionary origin of keratinized skin appendages and also help to better understand the regulation of hair in humans. "Our publication will stimulate further exciting studies in basic and preclinical research," concludes Leopold Eckhart.